Verana and Guardant to combine clinicogenomic and real-world data for precision oncology research

Verana Health and Guardant Health have formed a new collaboration to link curated electronic health record (EHR) datasets with genomic testing data, supporting biomarker research and therapy development across multiple cancer types.

The collaboration reflects growing demand for integrated resources that combine clinical, molecular, and longitudinal patient information to support oncology evidence generation. By enabling access to linked clinicogenomic and real-world datasets, the partnership is intended to strengthen researchers’ ability to evaluate treatment patterns, assess outcomes, and refine therapeutic strategies.

The combined resources will provide access to data from more than 95 million patients and include contributions from over 20,000 clinicians across academic medical centers and community care settings. In addition to supporting clinical trials and regulatory submissions, these data are also used to inform health economics research and market access planning.

Under the agreement, biopharmaceutical researchers will be able to use Verana Health’s regulatory-grade, therapeutic-specific EHR datasets alongside Guardant Health’s clinicogenomic testing data. Verana Health’s curated datasets draw on information from academic and community medical centers and capture detailed insights on patient care pathways, while Guardant Health contributes longitudinal genomic testing data spanning the disease course, from initial tumor profiling through recurrence and response monitoring.

The integration of these data sources is expected to support deeper analysis of relationships between molecular biomarkers, treatment decisions, and clinical outcomes across patient populations. The availability of longitudinal and serial testing information may also enable researchers to validate biomarker measures and refine patient selection strategies across diverse clinical settings. In addition, the combined datasets are expected to expand Verana Health’s oncology capabilities, particularly in solid tumors such as lung, breast, and colorectal cancers, supporting broader and more diverse patient representation in research.

Sujay Jadhav, CEO of Verana Health, explained the role of integrated datasets in advancing precision medicine research, stating:

“Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient.”

He added that linking Guardant Health’s data with Verana Health’s oncology and urology assets will help researchers “anticipate treatment responses and accelerate drug development for existing and new population segments.”

Craig Eagle, MD, Chief Medical Officer at Guardant Health, highlighted the value of connecting detailed biological insights with real-world clinical outcomes. He noted that:

“Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical as well.”